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ABSTRACT: Background: Advances in the treatment of Parkinson’s disease (PD) and changes in general life
expectancy may have improved survival in patients with PD.
Objective: The objective of this study was to investigate recent trends in PD mortality.
Methods: In total, 1521 patients with PD in local and national registries were followed for 11 years (2006–2016)
from diagnosis until exit date or death, and the causes of death were recorded.
Results: The survival of men with PD improved during the follow-up period, but no change was observed in
women (2-year postdiagnosis survival in men, 79.0%–86.3%, P = 0.03; 2-year postdiagnosis survival in women,
82.8%–87.5%, P = 0.42). Pneumonia was the most common immediate cause of death.
Discussion: The survival of men with PD has improved in Finland without a similar change in women. Because
changes in treatment likely affect both sexes similarly, the results may reflect the decreasing sex gap in life
expectancy. This phenomenon will likely increase the already high male-to-female prevalence ratio of PD.
Parkinson’s disease (PD) is associated with increased mortality, as,
on average, survival is reduced by approximately 5% every year in
followed cohorts.1 Although studies have demonstrated the
effectiveness of monoamine oxidase-B inhibitors,2–6 dopamine
agonists,7–11 and levodopa12,13 in the earlier stages of PD, the effects
of antiparkinsonian medications on PD mortality remain specula-
tive. In recent years, in line with new evidence, the traditional view
of early pharmacotherapy has started to shift from delayed levodopa
at advanced stages of PD to earlier initiation of low-dose therapy
for improved quality of life.14–16 Otherwise, the primary pharmaco-
therapy for early and moderate PD has remained mostly unaltered
for the past two decades in developed countries,17–19 and there are
no sex-specific recommendations for drug therapy in PD.20
The greatest improvements in PD treatment have recently been
documented in patients with advanced PD. Device-aided thera-
pies have induced treatment effects that appear to surpass those of
optimal oral drug therapy in advanced PD.21–25 However,
although deep brain stimulation and pump therapies induce clear
effects on quality of life in advanced PD, there is a similar lack of
current evidence for increased survival.21,23–26 Nevertheless, there
are potentially highly relevant changes in treatment that could
affect mortality, namely, improved rehabilitation, fall prevention,
and changes in the end-of-life care for patients with PD.27–31
It is hypothesized that changes in the care of PD have increased
the life expectancy (LE) of patients with PD. Nevertheless, as a
late-life neurodegenerative disease, PD epidemiology is also
affected by general factors that increase or decrease LE. Moreover,
the sex gap in LE has been reported to narrow.32 Here, we inves-
tigated possible changes in the mortality of a large hospital-based
cohort of Finnish patients with PD in three different time points
with respect to time of PD diagnosis by following a total of 1521
patients with PD in local and national registries for 11 years and
taking into account the effects of device-aided therapies, causes of
death, and general changes in LE.
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The Turku Clinical Research Center (http://www.turkucrc.fi/
en) maintains the Turku University Hospital database, which
stores all electronic health records generated at the hospital for
medical research. Health records have been in electronic format
from January 1, 2004, onward, enabling annual longitudinal ana-
lyses, and they include demographics, clinical diagnoses and pro-
cedures, inpatient periods and outpatient visits, pathology
diagnoses and reports, imaging reports, chemotherapy and
radiation treatments, inpatient medications and outpatient pre-
scriptions, laboratory measurements, and clinical narratives. At
present, the database contains detailed clinical data of approxi-
mately 0.5 million patients who have visited Turku University
Hospital or regional hospitals. The data are pseudonymized,
protecting the identity of the patients while making it possible to
link data elements to individual patients.
The study population consisted of patients with PD diagnosed
between 2006 and 2014 at Turku University Hospital in south-
western Finland. The hospital district has a population base of
approximately 470,000 people. Our study cohort included only
patients from the university hospital database, and the great
majority of diagnoses were based on outpatient visits. We
employed a methodological approach that involved the investi-
gations of complete, digital, detailed individual health records
during a period of 11 years. Patients with PD were identified
from the digital database using the International Classification of
Diseases 10th Revision code G20. All diagnoses of PD were based
on clinical examination by a certified neurologist using the UK
Brain Bank Criteria or Movement Disorder Society clinical
diagnostic criteria.33 The date of diagnosis was defined as the first
appearance of the diagnosis code in the patient records. After
identifying patients and diagnosis dates, all individual clinical data
were collected from the database. Dates and individual causes of
death were obtained from the national authority, Statistics
Finland (www.stat.fi). The beginning of the follow-up period
was January 1, 2006, and the end of the follow-up period was
set to December 31, 2016.
To investigate possible longitudinal changes in survival, the
cohort was divided into the following three groups based on the
year of diagnosis: 2006 to 2008, 2009 to 2011, and 2012 to
2014. Data analysis was separately performed for a sample in
which patients with device-aided therapies were excluded. The
overall survival (OS) was defined as the percentage of patients
who were still alive after their diagnosis at the following time
points: 1, 2, and 4 years. Hence, survival was investigated identi-
cally for every patient with PD at 1 and 2 years from the diagno-
sis. Therefore, our main result of the OS at 2 years after
diagnosis has been evaluated similarly and is valid for all patients.
The 4-year time point was evaluated similarly for the 2006 to
2008 and 2009 to 2011 groups. However, because the end of
our follow-up was set at December 31, 2016, the result of the
TABLE 1 Demographic characteristics of the patients and changes in the overall survival according to the year of PD diagnosis
Year of






Overall Survival, M/W, %a
Hazard Ratio







2006–2008 271/256 (51.4/48.6) 72.2/74.3 191/154 86.0/89.8 79.0/82.8 62.0/69.1 –
2009–2011 261/225 (53.7/46.3) 71.7/74.2 122/96 90.4/94.2 82.8/88.4 67.8/74.7 0.80 (0.63–1.01, 0.057)/
0.92 (0.70–1.20, 0.534)
2012–2014 292/216 (57.5/42.5) 71.0/73.8 75/47 91.1/93.1 86.3/87.5 71.5/77.3 0.71 (0.53-0.95, 0.019)/
0.79 (0.56–1.12, 0.191)
Total 824/697 (54.2/45.8) 71.6/74.1 388/297 –
aP value for Kaplan-Meier analysis: M, P = 0.03; W, P = 0.42.
M, men; W, women; Cl, confidence interval.
FIG. 1. Demographic characteristics of the sample according to the year of Parkinson’s disease diagnosis: (A) number of new diagnosis,
(B) age at diagnosis, and (C) overall survival 2 years after diagnosis according to follow-up period. Note the increased overall survival in
men but not in women in C. I = diagnosis years 2006 to 2008, II = diagnosis years 2009 to 2011, III = diagnosis years 2012 to 2014.
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OS 4 years after diagnosis in patients with PD diagnosed
between 2012 and 2014 was estimated using the Kaplan-Meier
analysis. To investigate possible differences in the correctness of
PD diagnoses between men and women, changed or removed
diagnoses were investigated within a 2-year timeline in 2011
(midpoint of the follow-up period). We also analyzed potential
changes in antiparkinsonian medication according to sex.
The study was approved by Turku Clinical Research Center
(TT263/2017, diary number TK-53-652-18). Because the study
did not involve patient contacts, approval of the ethics commit-
tee was not required.
Continuous and categorical variables were compared between
groups using analysis of variance and chi-square tests, respectively.
Kaplan-Meier analysis was used to analyze changes in the OS. Log-
rank tests were used to calculate the P values between survival
curves. The level of statistical significance was set to P < 0.05. All
statistical analyses were performed with IBM SPSS Statistics for
Windows (version 25.0, 2017, IBM Corp., Armonk, NY).
Results
We identified 1521 patients with PD (54.2% men; Table 1,
Fig. 1). The number of new diagnoses of PD per year remained
stable during the study period (men, 261–292 diagnoses per three
years, P = 0.14; women, 216–256 diagnoses per three years,
P = 0.14). Men were diagnosed at a younger age than women
(71.6 years [SD, 10.5 years] vs. 74.1 years, [SD, 10.4 years];
P < 0.01), but the age difference and mean age at diagnosis
remained stable (men, P = 0.41; women, P = 0.84). In 2011, at
the midpoint of the follow-up period, 55 men and 54 women
were diagnosed with PD. Two years later, the diagnoses
remained unaltered for 42 of men (76.4%) and 42 of women
(77.8%). There were no significant differences in the diagnostic
inaccuracy between men and women (men, 23.6%; women,
22.2%; P = 0.86; Supplementary Table S1). During the 11-year
study period, 685 patients died (47.1% of men and 42.6% of
women). The OS of male patients with PD increased during the
follow-up period (P = 0.03), but no change was observed in
women (P = 0.42; Table 1, Fig. 1). The hazard ratio for men in
the last follow-up period was 0.71 (95% confidence interval,
0.53–0.95; P = 0.02), indicating better survival for men if the
diagnosis was made later in the follow-up period. The results
remained the same when patients receiving device-aided thera-
pies (n = 29) were excluded from the analysis. The number of
patients with PD using levodopa and dopamine agonists
remained stable during the study period in both sexes (levodopa:
men, 55.2%–60.6% per three years, P = 0.39 and women, 54.2%–
60.2% per three years, P = 0.41; dopamine agonists: men, 40.6%–
43.8% per three years, P = 0.72 and women, 38.2%–41.8% per
three years, P = 0.24; Supplementary Table S2).
Pneumonia was the most common immediate cause of death
in all 3 time periods in both men and women (38.2% of deaths in
men and 25.9% of deaths in women; Table 2). The second and
third most common causes of death were heart failure and myo-
cardial infarction, respectively. There were no marked changes in
the causes of death during the study period. PD was reported as a
contributing factor to death in 36.3% of men and 38.4% of
women, and the percentage did not change significantly during
the follow-up period (men, 40.3% vs. 33.6% vs. 30.7%, P = 0.25;
women, 41.6% vs. 35.4% vs. 34.0%, P = 0.50; Table 2).
Discussion
The results demonstrate that the mortality of male Finnish
patients with PD has decreased during a period of 11 years. No
significant changes in the mortality of female patients with PD
were observed. In Finland, the diagnostic criteria and treatment
lines of PD are regionally homogeneous and are based on
national current care guidelines. Therefore, the result could
reflect greater improvements in male survival compared with
female survival at the population level, and the same sex differ-
ences can likely be seen in other regions with aging PD
populations and comparable health care systems.
Competing causes of death refers to an epidemiological fact
that if a patient is cured and will not die from one disease, he or
she is eligible to have another fatal disease. The most important
reason for the demonstrated change in the LE of male patients
with PD could be caused by population-level changes in
TABLE 2 The 3 most common immediate causes of death in the studied cohorts (I, II, III) in patients with PD according to sex and
year of diagnosis
Cohort
PD as a Contributing
Factor, n/%Year of Diagnosis Gender I, n/% II, n/% III, n/%
2006–2008 M Pneumonia (72/37.7) HF (7/3.7) MI (3/1.6) 77/40.3
W Pneumonia (45/29.2) HF (5/3.2) MI (5/3.2) 64/41.6
2009–2011 M Pneumonia (49/40.2) MI (5/4.1) CA (2/1.6) 41/33.6
W Pneumonia (22/22.9) MI (3/3.1) HF (2/2.1) 34/35.4
2012–2014 M Pneumonia (27/36.0) HF (4/5.3) MI (2/2.7) 23/30.7
W Pneumonia (10/21.3) MI (3/6.4) HF (2/4.3) 16/34.0
Total M Pneumonia (148/38.2) HF (12/3.1) MI (10/2.6) 141/36.3
W Pneumonia (77/25.9) MI (11/3.7) HF (9/3.0) 114/38.4
The immediate cause of death was not reported for 43.6% of men and 57.2% of women.
PD, Parkinson’s disease; M, men; W, women; HF, heart failure; MI, myocardial infarction; CA, cardiac arrest.
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morbidity and mortality. Between 2006 and 2016, the general
LE of Finnish newborns increased by 1.3 years in girls and
2.6 years in boys.34 Similarly, in 73-year-old individuals in the
general population (mean age of the present PD population), the
LE increased almost twice as much in men compared with
women (1.1 vs. 0.6 years).32 The present results may thus at least
partially be related to the decreasing sex differences in survival.
There are several reasons for the increased LE in men in Finland,
but successful actions taken for the prevention and control of
noncommunicable diseases are probably contributing. Cardiovas-
cular diseases, cancers, chronic respiratory diseases, and diabetes
are the most important causes of death worldwide and have
affected more men than women.35 In Finland, the most impor-
tant cause of death has long been ischemic heart disease, and
age-standardized mortality for circulatory diseases has declined,
especially in men.36
Studies have reported that there are no differences in the type
of dopaminergic medication prescribed to women and men, but
men are often medicated with higher doses of levodopa both
orally and via infusion.20 This is most likely attributed to the
higher average body mass of men.20 However, the differences
may not be solely explained by differences in body weight, as
there are sex differences in levodopa bioavailability, irrespective
of body weight.37,38 In addition, men are more often treated
with deep brain stimulation than women in PD, although
women more commonly suffer from motor fluctuations and dys-
kinesia.20,39 Diagnostic conventions and pharmacotherapy for
PD remained essentially the same in Finland during the study
period, as did the proportion of male and female patients with
PD using levodopa and dopamine agonists in our cohort. We do
not suspect that sex differences in therapy were a major contrib-
uting factor in the results. Moreover, the results remained the
same when the small number of patients treated with device-
aided therapies were excluded from the analysis. We did observe
a slight difference in the ages at diagnosis between men and
women (mean difference of 2.5 years; men were diagnosed ear-
lier). It has been suggested that the phenotype of PD in women
may be more benign and that symptoms may begin later for
women than in men, which could explain this difference.20 It
should be noted that nonpharmacological therapies, including
physiotherapy, speech therapy, and occupational therapy, are
given mainly in local health care centers in Finland. These data
were not available for us, and this can be considered as a limita-
tion of our study because the convention and intensity of these
therapies might have changed during the follow-up period.
In summary, the present study shows that there is disparity in
mortality between male and female patients with PD, which will
probably lead to an increasing male-to-female ratio in PD
prevalence.
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